A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

13 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-19

Study Completion Date

2025-10-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this clinical trial is to learn about the effects of the study medicine (called Tafamidis 61milligrams (mg)) for the potential treatment of Transthyretin amyloid cardiomyopathy (ATTR-CM).

This study is seeking participants who were prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once.

We will examine the experiences of people receiving the study medicine. This will help us determine if the study medicine is safe and effective.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy

NCT02791230

Transthyretin (TTR) Amyloid Cardiomyopathy

COMPLETED PHASE3

A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

NCT04814186

Transthyretin Amyloid Cardiomyopathy

COMPLETED PHASE4

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

NCT06393465

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

ACTIVE_NOT_RECRUITING

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

NCT01994889

Transthyretin (TTR) Amyloid Cardiomyopathy

COMPLETED PHASE3

NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis

NCT06251778

Amyloidosis Amyloidosis Cardiac ATTR Amyloidosis Wild Type

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transthyretin Amyloid Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ATTR-CM patients in Korea

transthyretin amyloid cardiomyopathy (ATTR-CM) patients in Korea

Tafamidis 61 milligrams

Intervention Type DRUG

Tafamidis 61mg as provided in real-world practice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tafamidis 61 milligrams

Tafamidis 61mg as provided in real-world practice

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥19 years
* Patients diagnosed with ATTR-CM (ATTRwt and ATTRv) with tissue biopsy or nuclear scintigraphy
* Patients who was prescribed Tafamidis 61mg after being diagnosed with ATTR-CM and have taken Tafamidis 61mg at least once.